ATR and cancer: Although ATR inhibitors hold great promise for the treatment of cancer (18, 19), challenges remain, including the identification of reliable biomarkers to predict response to ATR inhibitors and concerns about toxic off-target effects in normal cells that undergo replication stress to a lesser extent.